The pharmaceutical industry is changing – challenging for some, but an open road to opportunity for others. And the latest opportunity in the world of pharma comes from a rapidly growing demand for Medical Science Liaisons (MSLs), says Dr. Martijn Bijker.
As more drugs come to market and pharma’s business model shifts from selling drugs directly to fostering earlier engagement, companies are looking for highly skilled scientifically- and clinically-trained candidates. Could this be an outlet for the overflowing pool of PhD (and MD) graduates produced every year?
So what is an MSL?
An MSL is the scientific and clinical disease expert within a pharmaceutical or biotech company. They’re the go-to person for any complex questions about a specific drug. That could include questions about the science behind the drug, the mode of action, the competitors’ drugs, side effects, clinical trials, research opportunities, and disease-related questions.
MSLs work at the interface between internal stakeholders in the company and external stakeholders in the field – called Key Opinion Leaders (KOLs). MSLs help to bring innovative new drugs to the market and provide education about the proper use of drugs that are already on the market. KOLs – broadly defined as leaders in their field – can be heads of departments at teaching hospitals, heads of pharmacies, professors of medicine, the CEO of a patient organisation, physicians involved in pharmaceutical clinical trials and sometimes clinical scientists themselves. In short, MSLs work with the most influential stakeholders in a therapeutic area.
MSLs help to bring innovative new drugs to the market and provide education about the proper use of drugs that are already on the market.